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Neoplastic meningitis complicating metastatic breast cancer often
portends a progressive rapid neurologic deterioration to a fatal
outcome. Neoplastic meningitis most commonly occurs in patients
with evidence of metastases at other sites. Effective treatment
usually requires control of both the meningeal and systemic
components of the disease. Treatment of the meningeal disease is
problematic because so few anticancer drugs attain therapeutic
concentrations in the CSF when administered by the intravenous
route. The standard therapeutic approach includes limited-field
radiation therapy to symptomatic sites or radiographically defin-
able areas of bulk disease, and administration of methothrexate in
doses of 5 to 12 mg intrathecally 2–3 times a week, usually in
combination with oral leucovorin (Howell, 1997). However, while
methotrexate is active against this disease, the CSF half-life is only
4.5–8 h (Bleyer and Dedrick, 1977; Shapiro et al, 1975), so twice a
week dosing is not a pharmacokinetically optimal schedule. High
doses of methotrexate administered systemically can maintain
effective CSF concentrations for somewhat longer periods of time
and clear this compartment of malignant cells in a large fraction of
cases (Glantz et al, 1998), but in many patients it is difficult to
integrate this regimen into other chemotherapeutic programmes
being used to control systemic disease. Not surprisingly, thera-
peutic outcome is generally poor and there are very few long term
survivors (Ongerboer de Visser et al, 1983; Giannone et al, 1986;
Hitchins et al, 1987; Nakagawa et al, 1992; Grossman et al, 1993;
Grant et al, 1994). 
Cytarabine (ara-C) is a cell cycle phase-specific agent whose
cytotoxicity is a function of both drug concentration and duration
of exposure. Maximum tumour cell kill is attained by maintaining
high concentrations in the micro-environment of the cancer cell
for prolonged periods of time (Graham and Whitmore 1970).
DepoCyte is a slow-release formulation of ara-C developed
Intrathecal treatment of neoplastic meningitis due to
breast cancer with a slow-release formulation of
cytarabine 
KA Jaeckle, S Phuphanich, MJ van den Bent, R Aiken, T Batchelor, T Campbell, D Fulton, M Gilbert, D Heros,
L Rogers, SJ O’Day, W Akerley, J Allen, S Baidas, SZ Gertler, HS Greenberg, S LaFollette, G Lesser, W Mason,
L Recht, E Wong, MC Chamberlain, A Cohn, MJ Glantz, JC Gutheil, B Maria, P Moots, P New, C Russell, W Shapiro,
L Swinnen and SB Howell 
From the M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center; Dr. Daniel den Hoed Cancer Clinic; Thomas Jefferson University Hospital;
Massachusetts General Hospital; Sharp Healthcare; Cross Cancer Institute; the Emory Clinic; Mt. Sinai Comprehensive Cancer Center; Wayne State University
Health Center; the John Wayne Cancer Institute; Memorial Hospital of Rhode Island; New York University Medical Center; Georgetown University Medical
Center; Ottowa Regional Cancer Center; University of Michigan Hospitals; Rush Cancer Institute; Comprehensive Cancer Center of Wake Forrest University;
Ontario Cancer Center; University of Massachusetts Medical School; Beth Israel Deaconess Medical Center; University of California, San Diego; University of
Colorado; University of Florida; Vanderbilt University Medical Center; University of Texas, San Antonio; Norris Cancer Center; Barrow Neurological Institute; and
Loyola University 
Summary DepoCyte is a slow-release formulation of cytarabine designed for intrathecal administration. The goal of this multi-centre cohort
study was to determine the safety and efficacy of DepoCyte for the intrathecal treatment of neoplastic meningitis due to breast cancer.
DepoCyte 50 mg was injected once every 2 weeks for one month of induction therapy; responding patients were treated with an additional
3 months of consolidation therapy. All patients had metastatic breast cancer and a positive CSF cytology or neurologic findings characteristic
of neoplastic meningitis. The median number of DepoCyte doses was 3, and 85% of patients completed the planned 1 month induction.
Median follow up is currently 19 months. The primary endpoint was response, defined as conversion of the CSF cytology from positive to
negative at all sites known to be positive, and the absence of neurologic progression at the time the cytologic conversion was documented.
The response rate among the 43 evaluable patients was 28% (CI 95%: 14–41%); the intent-to-treat response rate was 21% (CI 95%:
12–34%). Median time to neurologic progression was 49 days (range 1–515+); median survival was 88 days (range 1–515+), and 1 year
survival is projected to be 19%. The major adverse events were headache and arachnoiditis. When drug-related, these were largely of low
grade, transient and reversible. Headache occurred on 11% of cycles; 90% were grade 1 or 2. Arachnoiditis occurred on 19% of cycles; 88%
were grade 1 or 2. DepoCyte demonstrated activity in neoplastic meningitis due to breast cancer that is comparable to results reported with
conventional intrathecal agents. However, this activity was achieved with one fourth as many intrathecal injections as typically required in
conventional therapy. The every 2 week dose schedule is a major advantage for both patients and physicians. © 2001 Cancer Research
Campaign http://www.bjcancer.com
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1993). In DepoCyte the ara-C is encapsulated in the aqueous
chambers of a spherical 20 um matrix comprised of lipids
biochemically similar to normal human cell membranes (phospho-
lipids, triglycerides and cholesterol). The particles are suspended
in 0.9% NaCl saline. When stored at 2–8˚C, the drug remains
inside the particle; when injected into the CSF the particles spread
out throughout the neuraxis and, at the ambient temperature of
37˚C, slowly release the ara-C. The particles eventually disappear
from CSF and the lipids undergo degradation (Kohn et al, 1998).
Whereas a single injection of free unencapsulated ara-C maintains
cytotoxic concentrations in the CSF for <24 hours (Zimm et al,
1984), a single injection of 50 mg of DepoCyte maintains cyto-
toxic concentrations of ara-C in the CSF for >14 days in most
patients, and the drug distribution within the neuraxis is relatively
homogeneous (Kim et al, 1993). Thus, intrathecal administration
of DepoCyte is required just once every 2 weeks as compared to a
daily dose schedule which would theoretically be required to
maintain cytotoxic concentrations in the CSF following injection
of free unencapsulated ara-C. 
This paper reports on the efficacy and safety of DepoCyte
administered to the 51 patients with neoplastic meningitis
complicating their breast cancer. 
MATERIALS AND METHODS 
Study design 
The breast cancer patients included in this report were drawn
from 4 different trials which were open to patients with neo-
plastic meningitis due to any type of solid tumour. The first was an
open label, randomized, parallel-group multicentre trial in which
patients with cytologically documented solid tumour neoplastic
meningitis were treated with either intrathecal DepoCyte or with
intrathecal methotrexate (Glantz et al, 1999). 11 of the patients
included in the current report were treated in this previously reported
study. The other 3 trials were open-label, non-randomized single arm
trials the results of which have not been published. All trials utilized
the same eligibility criteria, dose schedule, definition of response,
and safety evaluation criteria. After informed consent was obtained,
patients were entered from a total of 21 institutions with the approval
of appropriate Institutional Review Boards; accrual commenced in
July, 1994 and the last patient was entered in April 1999. The data
cutoff date for this analysis was 8 August 2000. 
Patients 
The inclusion criteria required that patients have histologically
proven breast cancer, a Karnofsky Performance Status > 50%, no
uncontrolled infection other than HIV, and recovery from toxici-
ties of prior intrathecal treatment. All but 3 patients had a positive
CSF cytology within 14 days prior to entry; these 3 patients were
diagnosed on the basis of characteristic neurologic and MRI scan
findings. Required laboratory values for treatment were platelets
³ 80 000 and WBC³ 3000/mm3 (or ANC ³ 1000/mm3), creatinine
≤ 2 times the upper limit of normal and all other blood chemistries
< 3 times normal. Prior CNS radiation of any type was allowed if
completed any time up to the day of study entry, but prior IT
methotrexate for the treatment of known neoplastic meningitis was
not. Patients entering the study with symptomatic or radiologically
visible CNS disease were required to receive local radiation
therapy during the induction period but concurrent whole brain or
craniospinal radiation was not permitted. CSF compartmentaliza-
tion identified on a radioisotope flow study, or the need for a
ventriculo-peritoneal shunt excluded the patient from partici-
pation. Concurrent systemic chemotherapy was permitted for
treatment of disease outside of the meninges, but high
dose methotrexate (> 500 mg/m2 day-1), high dose ara-C (> 2 g/m2
day-1),high dose thio TEPA (> 300 mg/m2 day-1) or investigational
agents were not allowed.
DepoCyte treatment 
Figure 1 presents a schematic diagram of the study design. Patients
received DepoCyte 50 mg by intraventricular (IVT) or lumbar sac
(LP) injection once every 14 days for 2 doses during the induction
phase. Those responding at the end of the induction phase then
received 50 mg once every 14 days for 1 month and then once a
month for 2 months for a total of 3 months of consolidation
therapy. Unless already receiving dexamethasone, all patients
were treated with dexamethasone 4 mg bid p.o. or i.v. on days 1–5
of each cycle beginning concurrently with administration of the
DepoCyte. 
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Figure 1 Study schema Clinical and laboratory monitoring 
Before each cycle of therapy, patients underwent a complete neuro-
logic history and exam, measurement of haematologic and serum
chemistry parameters, a urinalysis, and assessment of CSF cytology.
An independent cytopathologist, blinded to the chronology of CSF
samples, reviewed all available CSF cytology slides after the patient
completed the study. All treatment decisions (whether or not to
continue therapy) were based on the reading of the local cytopathol-
ogist. Efficacy analyses were based on central cytology review
except when the slide could not be recovered. In these cases, the
report of the local institutional cytopathologist was utilized. 
Adverse events were graded according to the NCI common
Toxicity Criteria. Identification of episodes of arachnoiditis was
based on a standardized algorithm. Patients were scored as having
drug-related arachnoiditis if, within 4 days of drug injection, they
developed either neck rigidity, neck pain, or meningismus, or if
they developed any 2 of the following signs or symptoms at the
same time: nausea, vomiting, headache, fever, back pain, or
aseptic CSF pleocytosis. Arachnoiditis was graded on the basis of
the highest grade of any of the constellation of adverse events
captured by the algorithm as mild (grade 1), moderate (grade 2),
severe (grade 3), or life-threatening (grade 4). 
Assessment of response 
Patients were only scored as responders if their CSF cytology
converted from positive to negative at all sites (i.e. ventricle and/or
lumbar sac) previously shown to be positive, and they remained
neurologically stable by objective criteria at the time of the CSF
conversion. Patients were scored as non-responders if they had a
positive or suspicious cytology at the end of the induction period
(day 29), or if they suffered neurologic progression regardless of
CSF cytology status. Patients were considered evaluable for
response if they had a positive CSF cytology prior to treatment,
completed at least one cycle of DepoCyte therapy, and had adequate
post-treatment CSF cytologic analysis. Time to neurologic progres-
sion was defined as the time between the first day of study treatment
and the day the patient was scored as suffering neurologic progres-
sion on the basis of the physician’s global assessment of neurologic
status, or until death, whichever came first. 
RESULTS 
A total of 56 women with breast cancer were registered for treat-
ment. Figure 1 presents a schematic diagram of the treatment
plan. 53 patients actually received DepoCyte; 3 patients refused
treatment after initially consenting to study participation. 8
patients received treatment exclusively via lumbar puncture, 42
patients received intraventricular treatment exclusively via an
Ommaya reservoir, and 3 patients received at least one injection by
both routes. Table 1 shows the baseline demographic characteris-
tics of previously reported prognostic significance in solid tumour
neoplastic meningitis (Hitchins et al, 1987; Grossman et al, 1993),
including age, gender, race, presence or absence of AIDS and
Karnofsky performance status. 
As shown in Figure 2, a total of 177 treatment cycles were
given to the 53 patients who received drug (median 3
cycles/patient). 45 of the 53 (85%) patients receiving drug were
able to complete the planned 1 month of induction therapy; 8
(15%) were able to complete planned 3 month consolidation
phase of treatment. The median time on study was 87 days (range
1–797 days), and the median follow up was 571 days with a range
of 74–1313 days. 
10 of the 53 patients who received DepoCyt were not evaluable
for response; 3 did not have a positive baseline cytology on central
review, and 7 did not have sufficient post-treatment CSF cytology
examinations to permit assessment. 12 of the 43 patients evaluable
for response (28%) attained a response (95% confidence interval 14
to 41%). On an intent-to-treat basis the response rate was 21% (95%
confidence interval 12 to 34%). There was no association between
response and prior intrathecal chemotherapy, concurrent systemic
chemotherapy, or prior or concurrent CNS irradiation. For example,
whereas 3 of the 12 (25%) patients receiving concurrent systemic
chemotherapy attained a response, 9 of the 44 (20%) patients not
receiving concurrent systemic chemotherapy responded. 
Figure 3 shows a Kaplan-Meier plot of time to neurologic
progression for all patients registered. The median was 49 days
(range 1 to 515+ days); 11% of patients were projected to remain
free of neurologic progression at 6 months. Figure 4 shows a
Kaplan-Meier plot of overall survival. Median survival was 88 days
(range 1 to 515+ days), and projected survival at 1 year was 9%. 
Data on change in Karnofsky score between baseline and the
end of the induction were available for 42 patients. The median
pre-treatment Karnofsky score was 80. Table 2 shows that 2% of
the patients had an improved score, 43% had no change, and 55%
had a worse score at the end of the induction phase of treatment.
The mean change in score in the 42 patients actually completing
the 1 month induction phase of treatment was -10± 14% (SD). 
Table 3 presents information on adverse events. The drug-
related adverse events were generally transient, and resolved
by the end of the treatment cycle on which they occurred.
The only adverse events to occur on ³10% of cycles
were headache, nausea, vomiting and arachnoiditis. Headache
occurred on 11% of cycles, but of all the headaches that occurred,
90% were grade 1 or 2. It was difficult to distinguish arachnoiditis
caused by meningeal tumour infiltration from that caused by
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Table 1 Baseline characteristics of possible prognostic significance 
Total number of patients 56 
Median age, yrs (range) 50 (28–74) 
Race 
White 44 (78%) 
Non-white 12 (21%) 
Median Karnofsky score 80 
Prior IT chemotherapy 3a (5%) 
Prior CNS irradiation 13 (25%) 
Concurrent systemic chemotherapy 12 (22%) 
Concurrent CNS irradiation 13 (23%) 
aSingle dose of IT methotrexate only 
Table 2 Change in Karnofsky performance score during the induction
phase (to day 29) 
No. patients with data available 42 
Improved score 1 (2%) 
No change 18 (43%) 
Worse score 23 (55%) 
Mean change in scorea -10 ± 14% 
aEnd of Induction – Baseline, mean ± SD 
British Journal of Cancer (2001) 84(2), 157–163 © 2001 Cancer Research Campaignintrathecal drug administration. As shown in Table 3, arachnoiditis
occurred on 19% of cycles; of all the episodes of arachnoiditis,
88% were grade 1 or 2. Only 3 patients discontinued DepoCyte
treatment in association with an adverse event of any kind (drug-
related or non-drug-related). There was no evidence of any form of
cumulative toxicity due to DepoCyte treatment. 
DISCUSSION 
This series constitutes the largest group of breast cancer patients
with neoplastic meningitis treated with intrathecal agents reported to
date. All patients were prospectively treated according to the same
eligibility criteria, and with the same intrathecal chemotherapy
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Figure 2 Distribution of number of cycles of treatment received. Each horizontal bar represents an individual patient; the length of the bar indicates the
number of cycles received. Planned treatment consisted of 2 cycles during the induction phase, and 4 during the consolidation phase 
Figure 3 Kaplan-Meier plots of time to neurologic progression. Hash marks indicate patients who had not yet suffered neurologic progression as of the data
cutoff date 
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1.0regimen. Strict response and adverse event monitoring procedures
were utilized with blinded central cytology review. The patients
included in these trials were comparable to those reported in prior
series with regard to variables previously reported to be of prog-
nostic significance in this disease (Boogerd et al, 1991; Grossman et
al, 1993; Jayson et al, 1994; Balm and Hammack, 1996; Fizazi et al,
1996; Chamberlain et al, 1997). 
In patients with neoplastic meningitis, spontaneous clearing of
malignant cells from the CSF in combination with lack of neuro-
logic progression is uncommon. Thus, the response rate of 28%,
with a 95% confidence interval of from 14–41%, observed in this
trial likely reflects drug effect. It is important to note that the defi-
nition of response in these patients was quite stringent, requiring
both conversion of the CSF cytology from positive to negative,
and absence of neurologic progression according to objective
criteria. Methotrexate is the drug that is currently most commonly
used for the treatment of solid tumour neoplastic meningitis. Prior
to the development of DepoCyte, only two prospective controlled
trials were reported in patients with solid tumour neoplastic
meningitis. In the first of these (Hitchins et al, 1987), the fraction
of patients clearing their CSF of malignant cells was not reported.
In the second (Grossman et al, 1993), the definition of response
approximated that used in the current trial, and 8 of 28 patients
(29%) cleared their CSF of malignant cells. In making compar-
isons of response rates, it is important to note that the DepoCyte
response rate of 28% reported here was attained with dosing
once every 2 weeks, one fourth to one sixth of the customary
methotrexate dosing frequency. None of the former trials were
conducted with the same rigor as the current studies, and none
included a central blinded cytology review. 
Many clinicians have a nihilistic attitude toward the treatment of
solid tumour neoplastic meningitis. In part, this attitude is justified
due to poor responses, lack of clinical improvement even when the
CSF is cleared of malignant cells, and because patients with
neoplastic meningitis often have extensive systemic end stage
disease. However, there is a subset of patients in whom the
meningeal involvement is either the only known site of disease, or
the site that most directly threatens quality of life or survival. In
this subset, intrathecal treatment may be warranted as adequate
control of the meningeal disease may offer substantial benefit in
Treatment of neoplastic meningitis 161
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Figure 4 Kaplan-Meier plots of survival. Hash marks indicate patients alive at the data cutoff date 
Table 3 Number (%) of cycles on which a drug-related adverse event of the indicated grade occurred 
No. cycles = 177 
Grade of toxicity 1 2 3 4 All Grades 
Headache 6a (3%)b 12 (7%) 1 (0.5%) 1 (0.5%) 20 (11%) 
Nausea 8 (5%) 12 (7%) 1 (0.5%) 1 (0.5%) 22 (12%) 
Vomiting 7 (4%) 11 (6%) 0 0 18 (10%) 
Arachnoiditis 17 (10%) 12 (7%) 3 (2%) 1 (0.6%) 33 (19%) 
aIncludes all adverse events that were possibly, probably or definitely drug-related, or for which relationship to drug could not be determined which occurred on
³ 10% of cycles. bNumber of cycles in which the AE of the specified type and grade occurred.cPercent of total cycles on which the AE occurred. 
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1.0the form of prolonged time to neurologic progression and possibly
survival. 
The median time to neurologic progression was 49 days for the
breast cancer patients included in this group of studies. This is
similar to that of 58 days reported for DepoCyte-treated patients
with various forms of solid tumour neoplastic meningitis treated in
a prospective randomized controlled trial in which this drug was
compared to methotrexate (Glantz et al, 1999). In this controlled
trial, methotrexate treatment yielded a median time to neurologic
progression of 30 days which was significantly inferior to that
produced by DepoCyte (P < 0.007). Many patients with neoplastic
meningitis die of systemic or combined systemic and meningeal
disease, and as a result adequate control of the meningeal disease
may not impact on survival. The median overall survival of 88
days observed in the breast cancer patients treated with DepoCyte
was comparable to that reported in prior studies of this drug
(Glantz et al, 1999). Although a number of investigators have
reported on the treatment of neoplastic meningitis due to breast
cancer (Ongerboer de Visser et al, 1983; Boogerd et al, 1991;
Jayson et al, 1994; Fizazi et al, 1996; Chamberlain and Kormanik
1997), in none of these studies did all patients meet the same eligi-
bility criteria, receive the same treatment in a prospective manner,
and undergo evaluation on the basis of the same prospective-
ly defined outcome measures. Thus, valid comparisons of time to
neurologic progression and survival cannot be made.
Nevertheless, the average median survival reported was 13 weeks,
leaving open the question of whether DepoCyt improves overall
survival in this disease. 
Is it reasonable to expect that a slow-release formulation of ara-
C would have significant activity against neoplastic meningitis
due to breast cancer? Ara-C is a cell cycle specific antimetabolite
whose cytotoxicity is very sensitive to duration of exposure. When
ara-C was tested in the NCI 60 cell line panel, the median concen-
tration required to inhibit growth by 50% was 17 uM when the
exposure duration was 2 days, and 0.17 uM when the cells were
exposed for 6 days. Thus, a relatively modest increase in the
duration of exposure increased efficacy by 2 orders of magnitude.
Intrathecal administration of DepoCyte results in peak free ara-C
concentrations of 300 mM that decay with a half-life of 144 hours
(Kim et al, 1993). This is in contrast to a CSF half-life of 3.4
hours for free unencapsulated ara-C (Zimm et al, 1984), and a CSF
half-life of 4.5–8 hours for methotrexate (Shapiro et al, 1975;
Bleyer and Dermick, 1977). Thus, it is reasonable to expect that
DepoCyte should produce a response rate at least comparable to
that of standard agents even when administered less frequently. 
The most common adverse events associated with DepoCyte
therapy were those typical of other intrathecally administered
chemotherapeutic agents, including headache, nausea, vomiting, and
arachnoiditis. The only adverse events that occurred on >10% of
cycles were headache, nausea, vomiting and arachnoiditis. It is
important to note that a large fraction of patients with neoplastic
meningitis due to breast cancer have headache, as well as other symp-
toms and signs of meningeal irritation due to tumour infiltration of the
meninges, prior to the start of treatment. Arachnoiditis occurred on
19% of cycles, and 88% of the episodes were grade 1 or 2. Signs and
symptoms of arachnoiditis generally resolved in <4 days. 3 patients
discontinued therapy in association with an adverse event, but in none
of these cases was cessation of therapy due to the adverse event. The
development of an episode of arachnoiditis did not delay any subse-
quent on-schedule DepoCyte therapy. We conclude that the toxicity
of DepoCyte is acceptable in this patient cohort. 
The optimal duration of therapy of solid tumour neoplastic
meningitis in responding patients has not been defined for any
drug. When intrathecal methotrexate is used, it is common practice
to dose 2–3 times per week until the CSF is clear of malignant
cells, and then at less frequent intervals for weeks to months
depending on the status of other components of the disease. This
same approach was adopted for the breast cancer patients reported
here, although since DepoCyte maintains ara-C concentrations
such a prolonged period of time the dosing interval during the
initial phase of treatment was 2 weeks, and that during the consol-
idation phase was 4 weeks. This approach is consistent with the
recently issued practice guidelines for the management of
neoplastic meningitis (Grossman and Spence, 1999).
This analysis provides response rates, and time to neurologic
progression and survival data that can be compared with future
trials of intrathecal therapy in breast cancer patients. Further
improvements in therapy are urgently needed. Exploration of
combination intrathecal chemotherapy with DepoCyte and
methotrexate, or systemically administered high-dose metho-
trexate and intrathecal DepoCyte are warranted. 
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